Ardelyx (ARDX) Q4 2025 earnings review
IBSRELA Adoption Surges, Nearing Profitability Inflection
Ardelyx delivered a pivotal quarter driven by the accelerating adoption of IBSRELA, which grew 61% YoY to $86.6M. While XPHOZAH revenues collapsed 51% YoY due to the previously disclosed loss of Medicare coverage, the sequential stability ($27.8M) suggests the non-Medicare commercial strategy has found a floor. Most notably, the company is on the brink of profitability, narrowing its Net Loss to just $0.4M in Q4 (vs. $41M loss in Q1). Management issued bullish FY26 guidance for IBSRELA ($410-430M), projecting another 50%+ growth year, cementing it as the primary value driver.
🐂 Bull Case
IBSRELA is accelerating, not stabilizing. Revenue jumped from $78.2M in Q3 to $86.6M in Q4. FY26 guidance implies >50% growth, putting the $1B peak sales target firmly in view for 2029.
The company effectively reached breakeven in Q4 (Net Loss $0.4M) while maintaining a robust cash pile of $264.7M. This reduces dilution risk and funds the pipeline without external capital.
🐻 Bear Case
XPHOZAH has been relegated to a niche product. With Medicare coverage gone, revenue has flatlined around ~$27M per quarter. FY26 guidance ($110-120M) implies barely any growth from the Q4 run rate.
R&D expenses jumped 67% YoY in Q4 as the company launched the ACCEL Phase 3 trial and RDX10531 program. Operating profitability may be volatile as clinical costs escalate in 2026.
⚖️ Verdict: 🟢
Bullish. The execution on IBSRELA is flawless, and the financial bleeding has stopped. While XPHOZAH is no longer a growth engine, it is a stable cash contributor. The focus now shifts entirely to IBSRELA's march toward $1B sales.
Key Themes
IBSRELA: Accelerating Performance
IBSRELA continues to beat expectations. Revenue grew 11% sequentially and 61% YoY. Management raised the stakes with FY26 guidance of $410-430M, implying a significant step up from FY25's $274M. The driver is 'depth and breadth' of prescribing—physicians are not just trying it, they are adopting it as a standard for IBS-C patients dissatisfied with legacy therapies.
XPHOZAH: Structural Reset Confirmed
The XPHOZAH narrative has shifted from 'growth' to 'maintenance.' Revenue fell 51% YoY due to the exclusion from Medicare Part D (TDAPA transition). However, the metric to watch is sequential stability: Q3 ($27.4M) to Q4 ($27.8M) shows the commercial/non-Medicare base is holding. FY26 guidance suggests this product is now a steady ~$29M/quarter business, not a growth driver.
Pipeline Re-Activation
With commercial revenue stabilizing the ship, Ardelyx is aggressively restarting R&D. They launched the 'ACCEL' Phase 3 trial for IBSRELA in Chronic Idiopathic Constipation (CIC)—a market expansion opportunity. Simultaneously, they are advancing RDX10531 (next-gen NHE3 inhibitor) toward an IND in 2H 2026. This explains the 37% YoY jump in FY25 R&D spend.
Rising Operating Expenses
Execution comes at a cost. SG&A increased 30% YoY in FY25 to $337M, and R&D jumped 37% to $71.5M. While revenue is growing faster, the company forecasts FY26 Operating Expenses 'up to $520M' (vs $408M in FY25). This heavy spend ensures that while they are near breakeven, significant profit margins are likely pushed out to 2027.
Strong Cash Position
Ardelyx ended 2025 with $264.7M in cash and investments, up from $250.1M a year ago. Notably, they generated positive cash flow in 2H 2025. This balance sheet strength removes the immediate threat of dilutive financing, a common killer for mid-cap biotechs launching drugs.
Other KPIs
Reversing. A massive improvement from the deep losses earlier in the year (e.g., -$41M in Q1). The company is effectively operating at breakeven right now, though increased R&D spend in 2026 may cause this to fluctuate.
Accelerating on an aggregate basis (+22% YoY). Despite the XPHOZAH headwind (-$57M YoY decline), IBSRELA's surge (+$116M YoY increase) more than compensated for the loss.
Accelerating. Up 67% YoY ($13.7M in 24Q4). This reflects the cost of the new ACCEL Phase 3 trial and RDX10531 preclinical work. Investors should model this higher run-rate for FY26.
Guidance
Accelerating. The midpoint ($420M) implies ~53% YoY growth over FY25's $274M. This confirms the 'hockey stick' adoption curve is intact.
Stable. The midpoint ($115M) implies ~11% growth over FY25's $103.6M. However, considering Q4's annualized run-rate is ~$111M, this guidance implies flat-to-minimal sequential growth throughout 2026.
Accelerating. FY25 OpEx was ~$409M. A jump to $520M (+27%) indicates heavy investment in the pipeline and sales force. This will dampen EPS expansion despite revenue growth.
Stable. Management reiterated the target for IBSRELA to achieve blockbuster status in 2029. With FY26 guided at ~$420M, the CAGR required to hit $1B in three years remains steep but plausible given current momentum.
Key Questions
Expense Cadence vs. Profitability
With Operating Expenses guided up to $520M in FY26, and total revenue guidance at the midpoint of ~$535M ($420M + $115M), projected operating margins are extremely thin. Is the goal for FY26 to remain roughly breakeven, or should we expect a return to net losses due to the pipeline ramp?
XPHOZAH Clinical Conviction
XPHOZAH guidance suggests very low growth ($110-120M vs $111M annualized Q4 rate). Does this imply you have fully penetrated the non-Medicare market, or are you seeing churn that offsets new patient starts?
CIC Indication Economics
You launched the Phase 3 ACCEL trial for CIC. What is the estimated cost of this trial through 2027, and does the current cash balance ($265M) fully fund the company through the readout?